Our Efforts to Develop a COVID-19 Vaccine
GET TO KNOW DR. ANNALIESA ANDERSON, HEAD OF BACTERIAL VACCINES
PROFESSOR JOE SCHMITT TALKS TICK-BOURNE ENCEPHALITIS
HOW ARE VACCINES DEVELOPED?
WHAT YOU NEED TO KNOW ABOUT COVID-19
-Abrocitinib met all key endpoints, demonstrating statistically superior improvements in skin clearance, disease extent and severity, and itch compared to placebo- -Safety profile consistent with other pivotal studies of abrocitinib reported to date- Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in…